We recently published a list of 10 Hottest Mega-Cap Stocks So Far in 2025. In this article, we are going to take a look at where Boston Scientific (NYSE:BSX) stands against other hottest mega-cap stocks so far in 2025.
Many mega-cap stocks have started 2025 with a bang and we’ll be taking a closer look into each of them to learn why they’ve performed so well already.
If you skim the trends in the past two years, it should be clear that it’s worthwhile to look into mega-cap stocks that have gained a lot already. Investors who defied the conventional wisdom and doubled down on the mega-cap stocks last year have outperformed the benchmark index by a wide margin.
We used a stock screener and sorted public companies — those tagged by the screener as trading in the U.S. — with a market capitalization above $100 billion by their year-to-date (YTD) gains.
Will lightning strike again this year and take these stocks even higher by the end of 2025? It’s not rational to paint all these companies with the same brush, so let’s dive into the nitty gritty of each mega-cap stock in this list.
A surgeon examining a patient’s brain in an operating room, paramedics nearby.
Boston Scientific (BSX)
- YTD Total Return: 7.58%
Boston Scientific (NYSE:BSX) makes medical devices. One of their most notable achievements was the development of a special device used to open clogged arteries in the heart called “Taxus Stent.”
I’m broadly bullish on most big-cap medical companies in the long run due to demographic trends, and that bullishness extends here, though I do think you should be careful in the near term as BSX has been trading at nosebleed levels. The stock is up 59% in just the past year and trades at 39 times forward earnings.
Recently, Boston Scientific (NYSE:BSX) announced an agreement to fully acquire Bolt Medical, which develops a laser-based technology known as intravascular lithotripsy (IVL). This technology helps break up calcium deposits in arteries and restore healthy blood flow. The deal is valued at up to $664 million (including milestone payments) and is expected to be finalized in the first half of 2025.
On the financial side, the company reported strong third-quarter 2024 results, with net sales of $4.209 billion — a 19.4% increase year-over-year on a reported basis — driven by sales growth in both its MedSurg and Cardiovascular segments.
Overall, BSX ranks 5th on our list of hottest mega-cap stocks so far in 2025. While we acknowledge the potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BSX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
